Ytibira 500 Tablet contains Abiraterone Acetate 500 mg, a potent androgen biosynthesis inhibitor used primarily in the management of metastatic castration-resistant prostate cancer (mCRPC). Abiraterone Acetate selectively inhibits the enzyme CYP17A1, which is critical in the production of androgens not only in the testes but also in the adrenal glands and prostate tumor tissue. By suppressing androgen synthesis, Ytibira 500 effectively reduces circulating testosterone levels, thereby limiting the growth and proliferation of prostate cancer cells that rely on androgens for survival. This medication is indicated for use in combination with prednisone or prednisolone to mitigate mineralocorticoid excess-related side effects such as hypertension, hypokalemia, and fluid retention. Ytibira 500 should be administered orally on an empty stomach, as food intake can significantly increase Abiraterone plasma concentrations, potentially leading to enhanced toxicity. Patients receiving Ytibira require regular monitoring of liver function tests, blood pressure, serum potassium, and signs of adrenal insufficiency. Common adverse effects include fatigue, joint swelling, edema, and elevated liver enzymes. Ytibira 500 is contraindicated in patients with hypersensitivity to Abiraterone or any component of the formulation and should be used cautiously in individuals with pre-existing cardiovascular or hepatic conditions.